ZYBT

Zhengye Biotechnology Holding Limited (ZYBT) SWOT Analysis Analysis (2026)

Invetso Score: 2.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.8 (Weak)

Low leverage versus peers, with net debt to EBITDA below zero, provides balance-sheet flexibility that many more indebted competitors lack.

Debt to equity remains modest at 0.30, which reduces refinancing pressure relative to leveraged peers and supports financial resilience.

Current ratio of 1.14 indicates near-term liquidity coverage above distressed peers, limiting immediate working-capital strain.

Quick ratio of 0.82 is acceptable for a small-cap operator, though it still trails stronger-liquidity peers and constrains flexibility.

Weaknesses

Score:

Negative ROIC of -16.1% shows capital is destroying value, leaving ZYBT structurally behind profitable peers that compound invested capital.

Cash conversion cycle of 60.2 days ties up working capital longer than efficient peers, which weakens reinvestment capacity and margin durability.

Liquidity is only adequate, with a current ratio near 1.14 and quick ratio below 1.0, leaving less cushion than stronger peers.

The absence of disclosed operating and gross margins limits evidence of operating strength, while peers with stable margins typically show better earnings quality.

Opportunities

Score:

If management shortens the 60.2-day cash conversion cycle, ZYBT could release working capital faster than peers with similarly stretched operating cycles.

The low debt burden creates room to fund operational improvements without the balance-sheet constraints that limit more leveraged competitors.

Improving returns on invested capital would have outsized impact because peers with positive ROIC already enjoy compounding advantages that ZYBT currently lacks.

A stronger liquidity profile could narrow the gap with better-capitalized peers, improving resilience through cyclical demand or supplier stress.

Threats

Score:

Persistent negative ROIC threatens long-term competitiveness because peers generating positive returns can reinvest faster and widen structural gaps.

A 60.2-day cash conversion cycle exposes ZYBT to working-capital shocks that more efficient peers can absorb with less strain.

Sub-1.0 quick ratio increases vulnerability to short-term funding pressure relative to peers with stronger liquid asset coverage.

If operating performance does not improve, the company may remain at a disadvantage versus peers that convert capital into earnings more efficiently.

Overall Score

Score:

ZYBT’s structural positioning versus peers is weak because negative capital returns and stretched working capital outweigh its relatively low leverage and only adequate liquidity.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zhengye Biotechnology Holding Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →